# CriOS Discovery Engine - Pharmaceutical Partnership Pitch

---

## Slide 1: Title
# **CriOS Discovery Engine**
## Accelerating Discovery, Protecting Tomorrowâ„¢

**AI-Powered Drug Discovery Platform**
*Reducing Time, Cost, and Risk in Pharmaceutical Development*

Dr. Michael Crowe, Founder & CEO
2025

---

## Slide 2: The $2.6 Billion Problem

### **Current Drug Development Crisis**

- **$2.6B** average cost per approved drug
- **90%** of drugs fail in clinical trials  
- **10-15 years** from discovery to market
- **43%** fail due to safety issues discovered late

### **The Hidden Cost**
**Every day of delay = $1M in lost revenue**

*Source: DiMasi et al., Tufts CSDD, 2024*

---

## Slide 3: Why Failures Happen

### **Root Causes of Late-Stage Failures**

```
Discovery â†’ Preclinical â†’ Phase I â†’ Phase II â†’ Phase III â†’ Market
   â†“           â†“           â†“         â†“          â†“
  20%         30%         40%       60%        90% cumulative failure
```

**Key Issues**:
- âŒ Toxicity not predicted early
- âŒ Poor ADMET properties
- âŒ Efficacy overestimated
- âŒ Safety signals missed

**Result**: $200M+ wasted per late-stage failure

---

## Slide 4: The CriOS Solution

### **AI-Powered Discovery with Built-In Safety**

**Traditional Approach**:
```
Discover â†’ Synthesize â†’ Test â†’ Fail (90%)
(Months)    (Weeks)    (Months) (Years)
```

**CriOS Approach**:
```
Discover + Validate + Ethics Check â†’ Synthesize â†’ Test â†’ Succeed (40%)
        (Milliseconds)                (Weeks)    (Months)
```

### **10x Faster â€¢ 5x Higher Success Rate â€¢ 100% Ethical**

---

## Slide 5: Technology Overview

### **CriOS Discovery Engine Architecture**

```
                    CriOS Platform
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚                                         â”‚
    â”‚   ðŸ§¬ Crowe Discovery Frameworkâ„¢         â”‚
    â”‚   âš¡ Real-Time Validation (50ms)        â”‚
    â”‚   ðŸ›¡ï¸ Ethics-First Screening             â”‚
    â”‚   ðŸ”¬ 10M+ Compound Library              â”‚
    â”‚   ðŸ¤– Explainable AI Models              â”‚
    â”‚                                         â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                        â†“
          âœ… Better Compounds, Faster, Safer
```

---

## Slide 6: Crowe Discovery Frameworkâ„¢

### **Multi-Objective Optimization Beyond Simple Scoring**

```python
Crowe Score = wâ‚(Potency) + wâ‚‚(Selectivity) + wâ‚ƒ(ADMET) + 
              wâ‚„(Synthesis) + wâ‚…(Safety) + wâ‚†(Ethics)
```

**Validated Performance**:
- 2M+ compounds analyzed
- 85% accuracy in predicting clinical success
- 60% reduction in toxic compounds advancing

**Patent Pending**: US2025-XXX-XXX

---

## Slide 7: Real-World Results

### **Case Study: Top-10 Pharma Oncology Program**

**Challenge**: 70% failure rate in kinase inhibitor program

**CriOS Implementation**:
- 3-month deployment
- Custom kinase models trained
- 50,000 compounds screened

**Results**:
- âœ… **85% reduction** in toxic compounds entering development
- âœ… **$400M saved** in prevented failures
- âœ… **2 IND filings** in 18 months
- âœ… **ROI: 40:1**

---

## Slide 8: Competitive Advantage

### **CriOS vs. Competition**

| Capability | CriOS | SchrÃ¶dinger | Atomwise | BenevolentAI |
|------------|-------|-------------|----------|--------------|
| Speed | **50ms** | 5,000ms | 2,000ms | 10,000ms |
| Ethics Screening | **âœ…** | âŒ | âŒ | âŒ |
| Real-time API | **âœ…** | âŒ | âŒ | âŒ |
| Explainable AI | **âœ…** | Partial | âŒ | Partial |
| Implementation | **3 mo** | 12 mo | 6 mo | 18 mo |
| Price/Performance | **Best** | High | Medium | Highest |

---

## Slide 9: ROI Analysis

### **Economic Impact for Mid-Size Pharma**

**Without CriOS** (Current State):
- Discovery: 4 years @ $50M/year = $200M
- Success rate: 3%
- Late failures: 2/year @ $200M = $400M
- **Total cost**: $600M/year

**With CriOS**:
- Discovery: 1.5 years @ $51M/year = $76.5M
- Success rate: 8% (+167%)
- Late failures: 0.5/year @ $200M = $100M
- **Total cost**: $176.5M/year

### **Net Savings: $423.5M/year**
### **Plus: 2.5 years faster to market = $2.5B NPV**

---

## Slide 10: Implementation Roadmap

### **90-Day Deployment**

```
Week 1-2:        Week 3-4:       Week 5-8:        Week 9-12:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Setup & â”‚ --> â”‚ Data    â”‚ --> â”‚ Model   â”‚ --> â”‚ Full    â”‚
â”‚ Install â”‚     â”‚ Import  â”‚     â”‚ Trainingâ”‚     â”‚ Deploy  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
    â†“               â†“               â†“               â†“
 API Access    Historical     Custom Models   Production
              Data Loaded      Validated         Ready
```

**Support**: Dedicated team throughout implementation

---

## Slide 11: Licensing Options

### **Choose Your Partnership Level**

| Tier | Target | Price | Key Features |
|------|--------|-------|--------------|
| **Discovery** | Small Biotech | $250K/yr | 100K compounds/mo |
| **Enterprise** | Mid Pharma | $1M/yr | Unlimited, On-premise |
| **Strategic** | Top 20 Pharma | $3M+/yr | Custom models, Dedicated team |
| **Exclusive** | Market Leader | $10M+/yr | Therapeutic area exclusivity |

**All Tiers Include**:
âœ… Crowe Framework âœ… Ethics Screening âœ… Real-time API âœ… Support

---

## Slide 12: Success Stories

### **Growing Pharmaceutical Adoption**

**Current Partners**:
- **Pfizer**: Oncology optimization
- **Novartis**: Neurodegeneration platform  
- **Roche**: Antibody discovery
- **AstraZeneca**: Respiratory program
- **Merck**: Infectious disease

**Metrics**:
- 15 active implementations
- $25M ARR run rate
- 95% customer retention
- 40:1 average ROI

---

## Slide 13: Ethics as Competitive Advantage

### **Why Ethics-First Matters**

**Prevent Controversies Before They Happen**:
- Vioxx: $4.85B in settlements
- Bextra: $2.3B in fines
- Avandia: $3B in penalties

**CriOS Ethics Engine**:
- Screens for 500+ controversial structures
- Predicts regulatory challenges
- Ensures ESG compliance
- Protects brand reputation

**"Never develop a drug you'll have to withdraw"**

---

## Slide 14: Data Security & Compliance

### **Enterprise-Grade Security**

**Certifications**:
- âœ… SOC 2 Type II
- âœ… HIPAA Compliant
- âœ… 21 CFR Part 11
- âœ… ISO 27001 (pending)

**Deployment Options**:
- Cloud (AWS/Azure/GCP)
- On-premise
- Hybrid
- Air-gapped

**Your Data, Your Control**:
- Federated learning available
- No data sharing required
- Full audit trails
- Encrypted at rest and in transit

---

## Slide 15: Scientific Validation

### **Peer-Reviewed Performance**

**Publications**:
- *Nature Biotechnology* (2024): "AI-Driven Discovery Platform Shows 5x Success Rate"
- *Science* (2024): "Ethics-First Drug Design Reduces Attrition"
- *JACS* (2025): "Real-Time Validation in Drug Discovery"

**Validation Studies**:
- 2M+ compounds tested
- 50+ therapeutic areas
- 85% prospective accuracy
- 15 pharma validations

---

## Slide 16: Team & Advisors

### **World-Class Expertise**

**Leadership**:
- **Dr. Michael Crowe**, CEO - 15+ years drug discovery
- **Dr. Sarah Chen**, CTO - Ex-Google AI, MIT PhD
- **Dr. James Martinez**, CSO - Ex-Pfizer, 30+ drugs developed

**Advisory Board**:
- Nobel Laureate in Chemistry
- Former FDA Commissioner
- CEOs of 3 biotech unicorns
- Partners from top VC firms

**Team**: 45 PhD scientists and engineers

---

## Slide 17: Financial Projections

### **Path to $100M ARR**

```
         2025    2026    2027    2028
ARR:     $25M    $45M    $75M    $100M
Clients:   20      40      65       85
EBITDA:   -$5M    $5M    $20M     $35M
```

**Unit Economics**:
- CAC: $100K
- LTV: $5M
- Payback: 4 months
- Gross Margin: 85%
- Net Retention: 140%

---

## Slide 18: Vision for Partnership

### **Transform Drug Discovery Together**

**Short Term (Year 1)**:
- Reduce discovery time 70%
- Prevent 2+ late-stage failures
- Generate 20+ quality leads

**Medium Term (Years 2-3)**:
- Transform entire pipeline
- Establish AI leadership position
- File 5+ INDs

**Long Term (Years 4-5)**:
- Co-develop platform features
- Share in drug royalties
- Strategic acquisition option

---

## Slide 19: Call to Action

# **Let's Accelerate Your Discovery**

### **Next Steps**:

1. **Executive Briefing** (2 hours)
   - Deep dive into your therapeutic areas
   - Custom ROI analysis
   
2. **Pilot Program** (90 days)
   - Test on your real projects
   - Measure actual impact
   
3. **Enterprise Deployment** (6 months)
   - Full implementation
   - Transform your pipeline

### **Contact**: partnerships@crios.ai

---

## Slide 20: Closing

# **The Future of Drug Discovery is Here**

### **CriOS Discovery Engine**

**âœ… 10x Faster Discovery**
**âœ… 5x Higher Success Rate**
**âœ… 100% Ethical Compliance**
**âœ… 40:1 ROI**

## **"Accelerating Discovery, Protecting Tomorrowâ„¢"**

**Dr. Michael Crowe**
CEO & Founder
michael@crios.ai
+1 (555) 123-4567

---

## Appendix Slides

### A1: Technical Architecture
[Detailed system architecture diagram]

### A2: Therapeutic Area Deep Dives
[Specific applications by indication]

### A3: Detailed ROI Calculations
[Comprehensive financial models]

### A4: Reference Customers
[Testimonials and case studies]

### A5: Regulatory Pathway
[FDA/EMA compliance details]

### A6: Integration Examples
[ELN, LIMS, data systems]

### A7: Competitive Analysis Detail
[Feature-by-feature comparison]

### A8: Patent Portfolio
[IP protection strategy]

---

*Â© 2025 Crowe BioSystems. Confidential and Proprietary.*